Fox Run Management L.L.C. Increases Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Fox Run Management L.L.C. grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 69.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,435 shares of the company’s stock after purchasing an additional 8,342 shares during the quarter. Fox Run Management L.L.C.’s holdings in Amneal Pharmaceuticals were worth $162,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in AMRX. JPMorgan Chase & Co. increased its position in shares of Amneal Pharmaceuticals by 149.7% in the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after acquiring an additional 777,568 shares during the period. Geode Capital Management LLC raised its position in Amneal Pharmaceuticals by 11.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after purchasing an additional 378,136 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth approximately $2,946,000. Polar Asset Management Partners Inc. grew its position in shares of Amneal Pharmaceuticals by 122.5% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company’s stock worth $3,270,000 after buying an additional 216,400 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Amneal Pharmaceuticals by 16.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company’s stock valued at $11,689,000 after buying an additional 202,863 shares during the period. Institutional investors own 31.82% of the company’s stock.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gautam Patel sold 62,590 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total transaction of $501,345.90. Following the completion of the transaction, the director now owns 1,968,886 shares in the company, valued at approximately $15,770,776.86. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,240,000 shares of company stock valued at $43,754,000 in the last 90 days. Corporate insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $8.28 on Friday. Amneal Pharmaceuticals, Inc. has a 1 year low of $5.18 and a 1 year high of $9.48. The firm has a market cap of $2.57 billion, a price-to-earnings ratio of -12.18 and a beta of 1.05. The company has a 50-day moving average of $8.42 and a 200 day moving average of $8.37.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. During the same period in the prior year, the business posted $0.14 EPS. On average, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on AMRX shares. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Finally, Barclays lifted their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Buy” and an average target price of $10.80.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.